welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Sarepta Therapeutics and Jerry R. Mendell, M.D. to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and Jerry R. Mendell, M.D., Curran-Peters Chair of Pediatric Research and Professor of Pediatrics and Neurology, Nationwide Children’s Hospital and The Ohio State University; The Research Institute at Nationwide Children’s Hospital, will host a webcast conference call from the 23rd International Annual Congress of the World Muscle Society (WMS) in Mendoza, Argentina, on Thursday, October 4, 2018 at 7:00 a.m. Eastern Time / 8:00 a.m. local Argentina time. The call will focus on an update regarding Sarepta’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program and will be led by Dr. Mendell, a renowned researcher in the field of DMD.
rareRelated
-
Valeria Ricotti, MD, PhDDr Valeria Ricotti, originally from Ital...
-
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambu...The purpose of this study is investigate...
-
CRISPR: Gene editing and beyondhttps://youtu.be/4YKFw2KZA5o...
-
Promising new therapy spares muscle loss in Duchenne muscular dystrophyBUFFALO, N.Y. — A promising therapy fo...
-
First Duchenne Drug Approved by the FDAhttps://www.youtube.com/watch?v=xQWfXKL1...
-
Cure Duchenne Kicks Off Inaugural ‘Pinkies Up to CureDuchenne’ Fundraising CampaignA campaign hopes to raise awareness of D...
-
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with co...Duchenne muscular dystrophy (DMD) is one...